Bicara Therapeutics, founded in 2020, is a clinical-stage company striving to develop biologics for cancer patient treatments. Bicara uses tumor-targeting antibodies and the tumor-microenvironment aiming to impact the tumor site for a hardwearing effect. Working to advance cancer treatment for patients who have had difficulty with first- and second-line therapies, Bicara partners with chemistry, manufacturing, and controls (CMC) experts and professional protein engineers who have a history of progressing FDA-approved drugs. Bicara Therapeutics is headquartered in Cambridge, Massachusetts.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/12/2023 | Series C | $165MM | $xx.xx | $495.55MM | Acorn Bioventures, Aisling Capital, Bioqube Ventures, Braidwell Lp, Deerfield Management, Eight Roads Ventures, Fairmount, F-Prime Capital, Invus Piper Heartland Healthcare Capital, Janus Henderson Investors, Omega Funds, Premji Invest, Ra Capital Management, Red Tree Venture Capital, The Rise Fund, Tpg | |
Price per Share
$xx.xx
Shares Outstanding
119,599,872
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acorn Bioventures, Aisling Capital, Bioqube Ventures, Braidwell Lp, Deerfield Management, Eight Roads Ventures, Fairmount, F-Prime Capital, Invus Piper Heartland Healthcare Capital, Janus Henderson Investors, Omega Funds, Premji Invest, Ra Capital Management, Red Tree Venture Capital, The Rise Fund, Tpg
|
||||||
03/06/2023 | Series B | $108.23MM | $xx.xx | $274.39MM | Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, F-Prime Capital, Invus, Janus Henderson Investors, Omega Funds, Piper Heartland Healthcare Capital, Premji Invest, Ra Capital Management, Red Tree Venture Capital | |
Price per Share
$xx.xx
Shares Outstanding
105,595,101
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, F-Prime Capital, Invus, Janus Henderson Investors, Omega Funds, Piper Heartland Healthcare Capital, Premji Invest, Ra Capital Management, Red Tree Venture Capital
|
||||||
03/15/2021 | Series Seed | $81.79MM | $xx.xx | $136.32MM | Biocon | |
Price per Share
$xx.xx
Shares Outstanding
81,790,144
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Biocon
|